MedTrace Logo

Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease

NCT04674735 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-04-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a small group.

Conditions

  • Meniere Disease
  • Vertigo
  • Vertigo Vestibular

Interventions

DRUG

APSLXR

Oral coated tablets once a day for 60 days.

Sponsors & Collaborators

  • Apsen Farmaceutica S.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2025-01-31
Completion
2025-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04674735 on ClinicalTrials.gov